Relapse Rate and Time to First Relapse were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS)

Drug Category : Array
Conference Category : Array
Lead Author : Steinman L, et al.
Published Date : 05/04/2022
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2022/04/Steinman_Oral_Time-to-First-Relapse_AAN_2022.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top